Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?
Authors: Fokom Domgue J,  Schiffman M,  Wentzensen NH,  Gage JC,  Castle PE,  Raine-Bennett TR,  Fetterman B,  Lorey T,  Poitras NE,  Befano B,  Xie Y,  Miachon LS,  Dean M
Journal: J Clin Microbiol
Date: 2017 Aug
Branches: CGB, LTG, MEB
PubMed ID: 28515214
PMC ID: PMC5527412
Abstract: Inexpensive and easy-to-perform human papillomavirus (HPV) tests are needed for primary cervical cancer screening in lower-resource regions. In a convenience sample of 516 residual exfoliative cervical specimens from the Kaiser Permanente Northern California and U.S. National Cancer Institute Persistence and Progression Study, we assessed the agreement and clinical performance of a simple, inexpensive real-time PCR assay for the detection of 13 carcinogenic HPV types (the H13 assay; Hybribio, Hong Kong) that is marketed in limited-resource settings compared to previous testing by the Hybrid Capture 2 assay (HC2; Qiagen, Germantown, MD) and the Onclarity assay (BD Diagnostics, Sparks, MD). The test set was chosen to include many HPV-positive specimens. The reference standard was a combination of HC2 and Onclarity results for HPV detection and histologic diagnosis of controls (less than cervical intraepithelial neoplasia grade 2 [